Forteo：飽和市場における画期的治療法の導入ケーススタディ

Forteo: A Case Study in Launching a Breakthrough Therapy in a Saturated Market

発行	Decision Resources, Inc.
出版日	2006年10月	商品コード	45798
ページ情報	英文 16 Pages
価格	こちらの商品の販売は終了いたしました。

概要
原文目次
関連レポート

当商品の販売は、2011年12月21日を持ちまして終了しました。

原文目次

Abstract

Introduction

The osteoporosis market has grown near% per year sin00, presenting many
opportunities for drug manufacturers. However, several effective, well-established, and
reasonably priced agents dominate the market. Even novel therapies satisfying a distinct need
face tremendous challenges when launched in this competitive arena.

Get the Answers You Need to Shape Your Strategy

Eli Lilly' s bone-building drug Forteo (teriparatide) was a promising breakthrough treatment for osteoporosis that achieved disappointing sales and relatively low acceptance among patients and physicians. Why did Forteo fail to meet early expectations for its use? Several issues during Forteo' s development phase greatly affected its launch and initial uptake. What are some problems that can hinder the uptake of a breakthrough therapy? What lessons can be learned from Forteo' s development and launch? Even an effective novel agent may face challenges when placed in a market that is saturated with well-established therapies. What factors must drug developers consider when developing and launching new agents?

Scope

Overview of osteoporosis: disease description, prevalence, and economic burden.
Current market for osteoporosis therapies: overview of common agents used to treat osteoporosis.
Case study of Forteo: development and approval, launch and early performance, outlook, lessons to be learned.